Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Laura Van T Veer, PhD

    TitleProfessor
    SchoolUCSF School of Medicine
    DepartmentLaboratory Medicine
    Address2340 Sutter Street
    San Francisco CA 94143
    Phone415-476-6023

       ORNG Applications 
       Websites
       In The News

       Bibliographic 
       Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Knauer M, Mook S, Rutgers EJ, Bender RA, Hauptmann M, van de Vijver MJ, Koornstra RH, Bueno-de-Mesquita JM, Linn SC, van 't Veer LJ. The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer. Breast Cancer Res Treat. 2010 Apr; 120(3):655-61.
        View in: PubMed
      2. Broeks A, Braaf LM, Wessels LF, van de Vijver M, De Bruin ML, Stovall M, Russell NS, van Leeuwen FE, Van 't Veer LJ. Radiation-associated breast tumors display a distinct gene expression profile. Int J Radiat Oncol Biol Phys. 2010 Feb 1; 76(2):540-7.
        View in: PubMed
      3. Stephens PJ, McBride DJ, Lin ML, Varela I, Pleasance ED, Simpson JT, Stebbings LA, Leroy C, Edkins S, Mudie LJ, Greenman CD, Jia M, Latimer C, Teague JW, Lau KW, Burton J, Quail MA, Swerdlow H, Churcher C, Natrajan R, Sieuwerts AM, Martens JW, Silver DP, Langerød A, Russnes HE, Foekens JA, Reis-Filho JS, van 't Veer L, Richardson AL, Børresen-Dale AL, Campbell PJ, Futreal PA, Stratton MR. Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature. 2009 Dec 24; 462(7276):1005-10.
        View in: PubMed
      4. Mook S, Schmidt MK, Weigelt B, Kreike B, Eekhout I, van de Vijver MJ, Glas AM, Floore A, Rutgers EJ, van 't Veer LJ. The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age. Ann Oncol. 2010 Apr; 21(4):717-22.
        View in: PubMed
      5. Linn SC, Van 't Veer LJ. Clinical relevance of the triple-negative breast cancer concept: genetic basis and clinical utility of the concept. Eur J Cancer. 2009 Sep; 45 Suppl 1:11-26.
        View in: PubMed
      6. Reyal F, van Vliet MH, Armstrong NJ, Horlings HM, de Visser KE, Kok M, Teschendorff AE, Mook S, van 't Veer L, Caldas C, Salmon RJ, van de Vijver MJ, Wessels LF. A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the proliferation, immune response and RNA splicing modules in breast cancer. Breast Cancer Res. 2008; 10(6):R93.
        View in: PubMed
      7. Molloy T, van 't Veer LJ. Recent advances in metastasis research. Curr Opin Genet Dev. 2008 Feb; 18(1):35-41.
        View in: PubMed
      8. Broeks A, Braaf LM, Huseinovic A, Schmidt MK, Russell NS, van Leeuwen FE, Hogervorst FB, Van 't Veer LJ. The spectrum of ATM missense variants and their contribution to contralateral breast cancer. Breast Cancer Res Treat. 2008 Jan; 107(2):243-8.
        View in: PubMed
      9. Broeks A, Braaf LM, Huseinovic A, Nooijen A, Urbanus J, Hogervorst FB, Schmidt MK, Klijn JG, Russell NS, Van Leeuwen FE, Van 't Veer LJ. Identification of women with an increased risk of developing radiation-induced breast cancer: a case only study. Breast Cancer Res. 2007; 9(2):R26.
        View in: PubMed
      10. Bogaerts J, Cardoso F, Buyse M, Braga S, Loi S, Harrison JA, Bines J, Mook S, Decker N, Ravdin P, Therasse P, Rutgers E, van 't Veer LJ, Piccart M. Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial. Nat Clin Pract Oncol. 2006 Oct; 3(10):540-51.
        View in: PubMed
      11. Ruijs MW, Verhoef S, Wigbout G, Pruntel R, Floore AN, de Jong D, van T Veer LJ, Menko FH. Late-onset common cancers in a kindred with an Arg213Gln TP53 germline mutation. Fam Cancer. 2006; 5(2):169-74.
        View in: PubMed
      12. Rebbeck TR, Friebel T, Wagner T, Lynch HT, Garber JE, Daly MB, Isaacs C, Olopade OI, Neuhausen SL, van 't Veer L, Eeles R, Evans DG, Tomlinson G, Matloff E, Narod SA, Eisen A, Domchek S, Armstrong K, Weber BL. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2005 Nov 1; 23(31):7804-10.
        View in: PubMed
      13. Weigelt B, Peterse JL, van 't Veer LJ. Breast cancer metastasis: markers and models. Nat Rev Cancer. 2005 Aug; 5(8):591-602.
        View in: PubMed
      14. van 't Veer L. Laura van 't Veer, PhD: bringing tumor gene profiles into the clinic. Interview. JAMA. 2004 Aug 11; 292(6):675.
        View in: PubMed
      15. Voskuil DW, Bosma A, Vrieling A, Rookus MA, van 't Veer LJ. Insulin-like growth factor (IGF)-system mRNA quantities in normal and tumor breast tissue of women with sporadic and familial breast cancer risk. Breast Cancer Res Treat. 2004 Apr; 84(3):225-33.
        View in: PubMed
      16. Schmidt MK, van Leeuwen FE, Klaren HM, Tollenaar RA, van 't Veer LJ. [Genetic research with stored human tissue: a coding procedure with optimal use of information and protection of privacy]. Ned Tijdschr Geneeskd. 2004 Mar 20; 148(12):564-8.
        View in: PubMed
      17. Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, van 't Veer L, Garber JE, Evans GR, Narod SA, Isaacs C, Matloff E, Daly MB, Olopade OI, Weber BL. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2004 Mar 15; 22(6):1055-62.
        View in: PubMed
      18. Szabo CI, Schutte M, Broeks A, Houwing-Duistermaat JJ, Thorstenson YR, Durocher F, Oldenburg RA, Wasielewski M, Odefrey F, Thompson D, Floore AN, Kraan J, Klijn JG, van den Ouweland AM, Wagner TM, Devilee P, Simard J, van 't Veer LJ, Goldgar DE, Meijers-Heijboer H. Are ATM mutations 7271T-->G and IVS10-6T-->G really high-risk breast cancer-susceptibility alleles? Cancer Res. 2004 Feb 1; 64(3):840-3.
        View in: PubMed
      19. Weigelt B, Bosma AJ, van 't Veer LJ. Expression of a novel lacrimal gland gene lacritin in human breast tissues. J Cancer Res Clin Oncol. 2003 Dec; 129(12):735-6.
        View in: PubMed
      20. Weigelt B, Bosma AJ, Hart AA, Rodenhuis S, van 't Veer LJ. Marker genes for circulating tumour cells predict survival in metastasized breast cancer patients. Br J Cancer. 2003 Apr 7; 88(7):1091-4.
        View in: PubMed
      21. Broeks A, van 't Veer LJ, Ottenheim C, Hiel JA, Kleijer WJ, Weemaes C. [From gene to disease; ataxia telangiectasia]. Ned Tijdschr Geneeskd. 2003 Mar 1; 147(9):386-9.
        View in: PubMed
      22. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Bernards R, Friend SH. Expression profiling predicts outcome in breast cancer. Breast Cancer Res. 2003; 5(1):57-8.
        View in: PubMed
      23. Bosma AJ, Weigelt B, Lambrechts AC, Verhagen OJ, Pruntel R, Hart AA, Rodenhuis S, van 't Veer LJ. Detection of circulating breast tumor cells by differential expression of marker genes. Clin Cancer Res. 2002 Jun; 8(6):1871-7.
        View in: PubMed
      24. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002 Jan 31; 415(6871):530-6.
        View in: PubMed
      25. Van 't Veer LJ, De Jong D. The microarray way to tailored cancer treatment. Nat Med. 2002 Jan; 8(1):13-4.
        View in: PubMed
      26. Broeks A, Russell NS, Floore AN, Urbanus JH, Dahler EC, van T Veer MB, Hagenbeek A, Noordijk EM, Crommelin MA, van Leeuwen FE, van T Veer LJ. Increased risk of breast cancer following irradiation for Hodgkin's disease is not a result of ATM germline mutations. Int J Radiat Biol. 2000 May; 76(5):693-8.
        View in: PubMed
      27. van Dijk MA, Hart AA, van 't Veer LJ. Differences in estrogen receptor alpha variant messenger RNAs between normal human breast tissue and primary breast carcinomas. Cancer Res. 2000 Feb 1; 60(3):530-3.
        View in: PubMed
      28. Broeks A, Urbanus JH, Floore AN, Dahler EC, Klijn JG, Rutgers EJ, Devilee P, Russell NS, van Leeuwen FE, van 't Veer LJ. ATM-heterozygous germline mutations contribute to breast cancer-susceptibility. Am J Hum Genet. 2000 Feb; 66(2):494-500.
        View in: PubMed
      29. Bartelink H, Begg AC, Martin JC, van Dijk M, Moonen L, van 't Veer LJ, Van de Vaart P, Verheij M. Translational research offers individually tailored treatments for cancer patients. Cancer J Sci Am. 2000 Jan-Feb; 6(1):2-10.
        View in: PubMed
      30. Ligtenberg MJ, Hogervorst FB, Willems HW, Arts PJ, Brink G, Hageman S, Bosgoed EA, Van der Looij E, Rookus MA, Devilee P, Vos EM, Wigbout G, Struycken PM, Menko FH, Rutgers EJ, Hoefsloot EH, Mariman EC, Brunner HG, Van 't Veer LJ. Characteristics of small breast and/or ovarian cancer families with germline mutations in BRCA1 and BRCA2. Br J Cancer. 1999 Mar; 79(9-10):1475-8.
        View in: PubMed
      31. Taal BG, van Loon HJ, Kahn N, de Jong D, Vasen HF, van 't Veer LJ. [The role of genetic factors in the development of gastric cancer]. Ned Tijdschr Geneeskd. 1999 Feb 13; 143(7):342-6.
        View in: PubMed
      32. Kersten MJ, Surachno S, Koopman MG, van 't Veer LJ, Pals ST, van Oers MH. [Epstein-Barr virus in a donor kidney as a cause of non-Hodgkin lymphoma]. Ned Tijdschr Geneeskd. 1999 Feb 13; 143(7):360-4.
        View in: PubMed
      33. Bartelink H, Begg A, Martin JC, van Dijk M, van 't Veer L, van der Vaart P, Verheij M. Towards prediction and modulation of treatment response. Radiother Oncol. 1999 Jan; 50(1):1-11.
        View in: PubMed
      34. Lambrechts AC, van 't Veer LJ, Rodenhuis S. The detection of minimal numbers of contaminating epithelial tumor cells in blood or bone marrow: use, limitations and future of RNA-based methods. Ann Oncol. 1998 Dec; 9(12):1269-76.
        View in: PubMed
      35. Dallinga JW, Pachen DM, Wijnhoven SW, Breedijk A, van 't Veer L, Wigbout G, van Zandwijk N, Maas LM, van Agen E, Kleinjans JC, van Schooten FJ. The use of 4-aminobiphenyl hemoglobin adducts and aromatic DNA adducts in lymphocytes of smokers as biomarkers of exposure. Cancer Epidemiol Biomarkers Prev. 1998 Jul; 7(7):571-7.
        View in: PubMed
      36. Godschalk RW, Maas LM, Van Zandwijk N, van 't Veer LJ, Breedijk A, Borm PJ, Verhaert J, Kleinjans JC, van Schooten FJ. Differences in aromatic-DNA adduct levels between alveolar macrophages and subpopulations of white blood cells from smokers. Carcinogenesis. 1998 May; 19(5):819-25.
        View in: PubMed
      37. Ceha HM, Balm AJ, de Jong D, van 't Veer LJ. Multiple malignancies in a patient with bilateral retinoblastoma. J Laryngol Otol. 1998 Feb; 112(2):189-92.
        View in: PubMed
      38. Broeks A, de Klein A, Floore AN, Muijtjens M, Kleijer WJ, Jaspers NG, van 't Veer LJ. ATM germline mutations in classical ataxia-telangiectasia patients in the Dutch population. Hum Mutat. 1998; 12(5):330-7.
        View in: PubMed
      39. Van Zandwijk N, Van 't Veer LJ. The role of prognostic factors and oncogenes in the detection and management of non-small-cell lung cancer. Oncology (Williston Park). 1998 Jan; 12(1 Suppl 2):55-9.
        View in: PubMed
      40. de Lange MS, Top B, Lambrechts C, Maas RA, Peterse HL, Mooi WJ, van 't Veer LJ, Rodenhuis S. A method to monitor mRNA levels in human breast tumor cells obtained by fine-needle aspiration. Diagn Mol Pathol. 1997 Dec; 6(6):353-60.
        View in: PubMed
      41. Petrij-Bosch A, Peelen T, van Vliet M, van Eijk R, Olmer R, Drüsedau M, Hogervorst FB, Hageman S, Arts PJ, Ligtenberg MJ, Meijers-Heijboer H, Klijn JG, Vasen HF, Cornelisse CJ, van 't Veer LJ, Bakker E, van Ommen GJ, Devilee P. BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. Nat Genet. 1997 Nov; 17(3):341-5.
        View in: PubMed
      42. van Dijk MA, Floore AN, Kloppenborg KI, van 't Veer LJ. A functional assay in yeast for the human estrogen receptor displays wild-type and variant estrogen receptor messenger RNAs present in breast carcinoma. Cancer Res. 1997 Aug 15; 57(16):3478-85.
        View in: PubMed
      43. de Jong D, Richel DJ, Schenkeveld C, Boerrigter L, van 't Veer LJ. Oligoclonal peripheral T-cell lymphocytosis as a result of aberrant T-cell development in a cortical thymoma. Diagn Mol Pathol. 1997 Aug; 6(4):244-8.
        View in: PubMed
      44. Weeda G, Rossignol M, Fraser RA, Winkler GS, Vermeulen W, van 't Veer LJ, Ma L, Hoeijmakers JH, Egly JM. The XPB subunit of repair/transcription factor TFIIH directly interacts with SUG1, a subunit of the 26S proteasome and putative transcription factor. Nucleic Acids Res. 1997 Jun 15; 25(12):2274-83.
        View in: PubMed
      45. Alkema MJ, Bronk M, Verhoeven E, Otte A, van 't Veer LJ, Berns A, van Lohuizen M. Identification of Bmi1-interacting proteins as constituents of a multimeric mammalian polycomb complex. Genes Dev. 1997 Jan 15; 11(2):226-40.
        View in: PubMed
      46. Wolthuis RM, Bauer B, van 't Veer LJ, de Vries-Smits AM, Cool RH, Spaargaren M, Wittinghofer A, Burgering BM, Bos JL. RalGDS-like factor (Rlf) is a novel Ras and Rap 1A-associating protein. Oncogene. 1996 Jul 18; 13(2):353-62.
        View in: PubMed
      47. Hijmans EM, Voorhoeve PM, Beijersbergen RL, van 't Veer LJ, Bernards R. E2F-5, a new E2F family member that interacts with p130 in vivo. Mol Cell Biol. 1995 Jun; 15(6):3082-9.
        View in: PubMed
      48. van 't Veer LJ, van der Feltz MJ, van den Berg-Bakker CA, Cheng NC, Hermens RP, van Oorschot DA, Kievits T, Schrier PI. Activation of the mas oncogene involves coupling to human alphoid sequences. Oncogene. 1993 Oct; 8(10):2673-81.
        View in: PubMed
      49. Hateboer G, Timmers HT, Rustgi AK, Billaud M, van 't Veer LJ, Bernards R. TATA-binding protein and the retinoblastoma gene product bind to overlapping epitopes on c-Myc and adenovirus E1A protein. Proc Natl Acad Sci U S A. 1993 Sep 15; 90(18):8489-93.
        View in: PubMed
      50. van 't Veer LJ, Beijersbergen RL, Bernards R. N-myc suppresses major histocompatibility complex class I gene expression through down-regulation of the p50 subunit of NF-kappa B. EMBO J. 1993 Jan; 12(1):195-200.
        View in: PubMed
      51. van 't Veer LJ, Lutz PM, Isselbacher KJ, Bernards R. Structure and expression of major histocompatibility complex-binding protein 2, a 275-kDa zinc finger protein that binds to an enhancer of major histocompatibility complex class I genes. Proc Natl Acad Sci U S A. 1992 Oct 1; 89(19):8971-5.
        View in: PubMed
      52. Schrier PI, Versteeg R, Peltenburg LT, Plomp AC, van 't Veer LJ, Krüse-Wolters KM. Sensitivity of melanoma cell lines to natural killer cells: a role for oncogene-modulated HLA class I expression? Semin Cancer Biol. 1991 Feb; 2(1):73-83.
        View in: PubMed
      53. Rustgi AK, Van 't Veer LJ, Bernards R. Two genes encode factors with NF-kappa B- and H2TF1-like DNA-binding properties. Proc Natl Acad Sci U S A. 1990 Nov; 87(22):8707-10.
        View in: PubMed
      54. van 't Veer LJ, Burgering BM, Versteeg R, Boot AJ, Ruiter DJ, Osanto S, Schrier PI, Bos JL. N-ras mutations in human cutaneous melanoma from sun-exposed body sites. Mol Cell Biol. 1989 Jul; 9(7):3114-6.
        View in: PubMed
      55. Kuppen PJ, Schuitemaker H, van 't Veer LJ, de Bruijn EA, van Oosterom AT, Schrier PI. cis-diamminedichloroplatinum(II)-resistant sublines derived from two human ovarian tumor cell lines. Cancer Res. 1988 Jun 15; 48(12):3355-9.
        View in: PubMed
      56. van 't Veer LJ, Hermens R, van den Berg-Bakker LA, Cheng NC, Fleuren GJ, Bos JL, Cleton FJ, Schrier PI. ras oncogene activation in human ovarian carcinoma. Oncogene. 1988 Feb; 2(2):157-65.
        View in: PubMed
      57. van 't Veer LJ, van den Berg-Bakker LA, Hermens RP, Deprez RL, Schrier PI. High frequency of mas oncogene activation detected in the NIH3T3 tumorigenicity assay. Oncogene Res. 1988; 3(3):247-54.
        View in: PubMed
      58. van 't Veer LJ, van Kessel AG, van Heerikhuizen H, van Ooyen A, Nusse R. Molecular cloning and chromosomal assignment of the human homolog of int-1, a mouse gene implicated in mammary tumorigenesis. Mol Cell Biol. 1984 Nov; 4(11):2532-4.
        View in: PubMed
      Laura's Networks
      Click the "See All" links for more information and interactive visualizations!
      Related Concepts
      Derived automatically from this person's publications.
      _
      Related Authors
      People who share related concepts with this person.
      _
      Same Department
      Back to TOP